Some of the previous studies regarding asthma treatment used long acting beta – agonists which is one of the most common kinds of asthma medicine. These studies showed evidence for an adverse genotypic effect. For this new study researchers analyzed the effects of this most common therapy used in combination with inhaled corticosteroids in asthmatic patients who have specific beta -2 adrenergic genotype. During the study patients received one of two different long acting beta-agonists. Results of the research showed that symptoms of asthma improved in both groups but there was no difference based on this specific beta -2 adrenergic genotype.

This study is of great importance because of the fact that previous studies showed evidence for an adverse genotypic effect and this one showed conflicting results. Current studies advise usage of combined therapy with long-acting beta-agonists together with inhaled corticosteroids to control all kinds of asthma, from moderate to severely persistent one. Since the large numbers of patients was involved in this study and they received combination therapy it was reassuring that no adverse safety effects could be attributed to an individual’s genotype.